Successful Complete Response in an Elderly Patient with Occult Lung Squamous Cell Carcinoma

Overview

This case study reports a complete response in an 83-year-old man with occult lung squamous cell carcinoma (LUSC) treated with penpulimab and anlotinib.

Background

Occult lung cancer is a rare and aggressive form of non-small cell lung cancer (NSCLC), often leading to poor prognoses due to diagnostic challenges. The combination of immunotherapy and targeted therapies has shown promise in treating advanced NSCLC.

Data Highlights

No numerical or trial data available in the source material.

Key Findings

• An 83-year-old man with occult LUSC achieved a complete response after treatment with penpulimab and anlotinib.
• The patient had a mediastinal mass and multiple lymph node metastases confirmed by biopsy.
• The complete remission lasted over two years with no observed adverse effects.
• The therapy was continued for 26 months before being stopped at the patient’s request.
• PD-L1 expression was not assessed due to the patient's refusal, limiting conclusions on predictive factors.

Clinical Implications

Clinicians should consider the treatment options available for elderly patients with advanced LUSC who decline standard therapies.

Conclusion

This case highlights the treatment approach for occult LUSC in elderly patients.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. the asco post — Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
3. Frontiers in Oncology — Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma
4. Frontiers in Oncology — Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer – a case report and review of the literature
5. The ASCO Post — Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
6. Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
7. Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma
8. Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer – a case report and review of the literature
9. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
10. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial
11. [Table], Table 1. Definitions of TNM Occult Carcinomaa - PDQ Cancer Information Summaries - NCBI Bookshelf